WP1130 is a selective small molecular deubiquitinase (USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and a Bcr/Abl destruction pathway activator with an IC50 of 1.8 μM for K562 cells.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | ALK1 ↓ ↑ | ALK2 ↓ ↑ | ALK3 ↓ ↑ | ALK4 ↓ ↑ | ALK6 ↓ ↑ | Smad3 ↓ ↑ | TGF-β ↓ ↑ | TGFβRI/ALK5 ↓ ↑ | TGFβRII ↓ ↑ | 其他靶点 | 纯度 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LDN193189 |
++++
ALK1, IC50: 0.8 nM |
++++
ALK2, IC50: 0.8 nM |
+++
ALK3, IC50: 5.3 nM |
+++
ALK6, IC50: 16.7 nM |
99%+ | ||||||||||||||
LDN-212854 |
++++
ALK1, IC50: 2.4 nM |
++++
ALK2, IC50: 1.3 nM |
+
ALK3, IC50: 85.8 nM |
+
ALK4, IC50: 2133 nM |
+
ALK5, IC50: 9276 nM |
99%+ | |||||||||||||
ML347 |
++
ALK1, IC50: 46 nM |
++
ALK2, IC50: 32 nM |
98% | ||||||||||||||||
K02288 |
++++
ALK1, IC50: 1.8 nM |
++++
ALK2, IC50: 1.1 nM |
++
ALK3, IC50: 34.4 nM |
+++
ALK6, IC50: 6.4 nM |
99%+ | ||||||||||||||
LDN-193189 dihydrochloride |
++++
ALK1, IC50: 0.8 nM |
++++
ALK2, IC50: 0.8 nM |
+++
ALK3, IC50: 5.3 nM |
+++
ALK6, IC50: 16.7 nM |
99% | ||||||||||||||
LDN-214117 |
++
ALK2, IC50: 24 nM |
98% | |||||||||||||||||
DMH-1 |
+
ALK2, IC50: 107.9 nM |
99%+ | |||||||||||||||||
SB-505124 |
+
ALK4, IC50: 129 nM |
++
ALK5, IC50: 47 nM |
99%+ | ||||||||||||||||
Vactosertib |
+++
ALK4, IC50: 13 nM |
+++
ALK5, IC50: 11 nM |
99%+ | ||||||||||||||||
Alantolactone | ✔ | 98% | |||||||||||||||||
SIS3 | ✔ | 97% | |||||||||||||||||
Pirfenidone | ✔ | 98% | |||||||||||||||||
Hesperetin | ✔ | 97% | |||||||||||||||||
RepSox |
++++
TGFβR1(ALK5), IC50: 4 nM |
98% | |||||||||||||||||
GW788388 |
+++
ALK5, IC50: 18 nM |
98% | |||||||||||||||||
LY364947 |
++
TGFβRI, IC50: 59 nM |
+
TGFβRII, IC50: 0.4 μM |
98% | ||||||||||||||||
SD-208 |
++
TGF-βRI (ALK5), IC50: 48 nM |
98% | |||||||||||||||||
SB-525334 |
+++
TGFβR1(ALK5), IC50: 14.3 nM |
99%+ | |||||||||||||||||
LY2109761 |
++
TβRI, Ki: 38 nM |
+
TβRII, Ki: 300 nM |
99%+ | ||||||||||||||||
Galunisertib |
++
TβRI, IC50: 56 nM |
98% | |||||||||||||||||
SB 431542 |
+
ALK5, IC50: 94 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Abl ↓ ↑ | Bcr-Abl ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVP-BHG 712 |
+
c-Abl, IC50: 1.667 μM |
99%+ | |||||||||||||||||
KW-2449 |
+++
Abl (T315I), IC50: 4 nM Abl, IC50: 14 nM |
FLT3 | 99%+ | ||||||||||||||||
Ponatinib |
++++
Abl, IC50: 0.37 nM |
98% | |||||||||||||||||
AT9283 | 99%+ | ||||||||||||||||||
Imatinib Mesylate |
+
v-Abl, IC50: 600 nM |
c-Kit,PDGFR | 99% | ||||||||||||||||
Danusertib |
++
Abl, IC50: 25 nM |
RET | 99%+ | ||||||||||||||||
Rebastinib |
++++
u-Abl1 (T315I), IC50: 5 nM p-Abl1 (native), IC50: 0.75 nM |
Tie-2,FLT3 | 99%+ | ||||||||||||||||
PP121 |
++
Abl, IC50: 18 nM |
PDGFR,VEGFR | 99%+ | ||||||||||||||||
GNF-7 |
+++
E255V, IC50: 122 nM M351T, IC50: 133 nM |
99%+ | |||||||||||||||||
Olverembatinib dimesylate |
++++
Abl (G250E), IC50: 0.35 nM Abl, IC50: 0.34 nM |
99% | |||||||||||||||||
Dasatinib monohydrate |
++++
Abl , IC50: 0.6 nM |
Src | 98% | ||||||||||||||||
Dasatinib |
++++
Abl, IC50: 0.6 nM |
Src | 98% | ||||||||||||||||
Bafetinib |
+++
Abl, IC50: 5.8 nM |
98+% | |||||||||||||||||
GNF-2 |
+
Bcr-Abl (K562 cell line), IC50: 273 nM Bcr-Abl (SUP-B15 cell line), IC50: 268 nM |
98%+ | |||||||||||||||||
Degrasyn |
+
Bcr-Abl, IC50: 1.8 μM |
DUB | 98+% | ||||||||||||||||
GNF-5 |
++
Bcr-Abl, IC50: 220 nM |
98% | |||||||||||||||||
Radotinib |
++
BCR-ABL1, IC50: 34 nM |
98+% | |||||||||||||||||
PD173955 | Src | 99%+ | |||||||||||||||||
Nilotinib |
++
Bcr-Abl, IC50: <30 nM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | DUB ↓ ↑ | UCH ↓ ↑ | USP/UBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PR-619 |
+
Plpro, EC50: 14.2 μM |
+++
UCH-L5, EC50: 12.8 μM UCH-L3, EC50: 2.95 μM |
+++
USP5, EC50: 4.90 μM USP28, EC50: 6.24 μM |
99%+ | |||||||||||||||
Degrasyn | ✔ | Bcr-Abl | 98+% | ||||||||||||||||
VLX1570 |
+
DUB, IC50: ~10 μM |
99%+ | |||||||||||||||||
ML-323 |
++++
USP1-UAF1, IC50: 76 nM |
99%+ | |||||||||||||||||
LDN-57444 |
++++
UCH-L1, IC50: 0.4 μM UCH-L3, IC50: 25 μM |
99%+ | |||||||||||||||||
TCID |
++++
UCH-L3, IC50: 0.6 μM |
98% | |||||||||||||||||
b-AP15 |
+++
UCHL5, IC50: 2.1 μM |
98% | |||||||||||||||||
P 22077 |
++
USP7, IC50: 8.6 μM USP47, EC50: 8.74 μM |
99%+ | |||||||||||||||||
P005091 |
++
USP47, IC50: 4.3 μM USP7, EC50: 4.2 μM |
99+% | |||||||||||||||||
IU1 |
++
USP14, IC50: 4.7 μM |
98% | |||||||||||||||||
NSC632839 |
+
USP2, EC50: 45 μM USP7, EC50: 37 μM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | WP1130 is a partly selective DUB inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37, which are known to regulate survival protein stability and 26S proteasome function. WP1130 at 5μM induced rapid accumulation of polyubiquitinated (K48/K63-linked) proteins into juxtanuclear aggresomes, without affecting 20S proteasome activity. WP1130-mediated inhibition of tumor-activated DUBs resulted in downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53, in BV173 cells treated by 5μM WP1130 for 4h[3]. WP1130 at 5μM specifically and rapidly down-regulatef both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells, not requiring the participation of the proteasomal pathway. And this loss of Bcr/Abl protein correlated with the onset of apoptosis and reduced phosphorylation of Bcr/Abl substrates, including p-Stat5 and p-Hck. It was more effective in reducing leukemic versus normal hematopoietic colony formation and strongly inhibited colony formation of cells derived from patients with T315I mutant Bcr/Abl–expressing CML in blast crisis. WP1130 suppressed the growth of K562 heterotransplanted tumors of mice treated with WP1130 at 30mg/kg, i.p., every other day for 9 days[4]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human A375 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human A375 cells after 72 hrs by MTT assay, IC50=1.7 μM | 24457091 | |
human K562 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human K562 cells after 72 hrs by MTT assay, IC50=2.4 μM | 24457091 | |
human Mino cells | Cytotoxicity assay | 72 h | Cytotoxicity against human Mino cells after 72 hrs by MTT assay, IC50=0.8 μM | 24457091 | |
human MM1 cells | Function assay | 24 to 72 hrs | Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, IC50=1 μM | 22036213 | |
Dose | Mice: 20 mg/kg[3] (i.p.), 40 mg/kg[4] (i.p.) |
Administration | i.p. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.60mL 0.52mL 0.26mL |
13.01mL 2.60mL 1.30mL |
26.02mL 5.20mL 2.60mL |
CAS号 | 856243-80-6 |
分子式 | C19H18BrN3O |
分子量 | 384.27 |
别名 | Wp1130 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Inert atmosphere,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(273.25 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |